Colorectal Cancer clinical trials in Mississippi

8 actively recruiting colorectal cancer trials at 7 sites across Mississippi.

Data from ClinicalTrials.gov · last refreshed 2026-10-01

Phase 3 Recruiting Industry

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…

Sponsor: Janssen Research & Development, LLC

NCT ID: NCT06662786

Sites in Mississippi:

Hattiesburg Clinic — Hattiesburg, Mississippi

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…

Sponsor: Janssen Research & Development, LLC

NCT ID: NCT06750094

Sites in Mississippi:

Hattiesburg Clinic — Hattiesburg, Mississippi

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06997497

Sites in Mississippi:

Hattiesburg Clinic ( Site 0064) — Hattiesburg, Mississippi

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05673148

Sites in Mississippi:

Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
Baptist Cancer Center-Grenada — Grenada, Mississippi
Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) a…

Sponsor: Janssen Research & Development, LLC

NCT ID: NCT05379595

Sites in Mississippi:

Hattiesburg Clinic — Hattiesburg, Mississippi

View on ClinicalTrials.gov →

Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences

NCT ID: NCT06418204

Sites in Mississippi:

Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
Baptist Cancer Center-Grenada — Grenada, Mississippi
Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
Baptist Memorial Hospital and Cancer Center-Desoto — Southaven, Mississippi

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT07283939

Sites in Mississippi:

Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
Baptist Cancer Center-Grenada — Grenada, Mississippi
Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi

View on ClinicalTrials.gov →

Phase 4 Recruiting Industry

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory me…

Sponsor: Takeda

NCT ID: NCT06562543

Sites in Mississippi:

Hattiesburg Clinic — Hattiesburg, Mississippi

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01